Deadly Arrhythmias Less of a Risk for HF Patients on Dapagliflozin
An SGLT2 inhibitor seemed to offer protection from reduced ventricular arrhythmias in heart failure patients, according to a post hoc analysis of DAPA-HF. In that trial, the cohort randomized to dapagliflozin (Farxiga) had a reduced first occurrence of any ventricular arrhythmia, resuscitated cardiac arrest, or sudden death (5.9% vs 7.4% for placebo group; HR 0.79, […]
High-Dose HBV Revaccination Better Protects HIV Patients
In HIV patients who failed to achieve protection from the hepatitis B virus (HBV) vaccine, a high-dose revaccination schedule led to better serological responses versus standard dosing, a randomized single-center trial in Chile showed. In an intention-to-treat analysis involving over 100 patients, 72% of those revaccinated with three doses of a high-dose recombinant HBV vaccine […]